Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-low Hormone Receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06966700
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Who this might be right for
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC 2,400
Testing effectiveness (Phase 2)Looking for participantsNCT07287917
What this trial is testing

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Who this might be right for
Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc. 92
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Testing effectiveness (Phase 2)Active Not RecruitingNCT06008158
What this trial is testing

Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca

Who this might be right for
Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Estrogen Receptor-Positive Breast Carcinoma+1 more
City of Hope Medical Center 48
Large-scale testing (Phase 3)Looking for participantsNCT07391774
What this trial is testing

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Not applicableStudy completedNCT06040593
What this trial is testing

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

Who this might be right for
Hormone-receptor-positive Breast CancerHER2-low Breast CancerHER2-negative Breast Cancer
Daiichi Sankyo 927
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362
What this trial is testing

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Who this might be right for
Urinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more
BicycleTx Limited 329
Testing effectiveness (Phase 2)Looking for participantsNCT06797635
What this trial is testing

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 372
Large-scale testing (Phase 3)Active Not RecruitingNCT06018337
What this trial is testing

DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Who this might be right for
Metastatic Breast Cancer
DualityBio Inc. 541
Testing effectiveness (Phase 2)Ended earlyNCT02236572
What this trial is testing

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Who this might be right for
Breast Cancer
Yale University 17
Testing effectiveness (Phase 2)Looking for participantsNCT04553770
What this trial is testing

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Who this might be right for
Early-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more
Jonsson Comprehensive Cancer Center 88
Testing effectiveness (Phase 2)Looking for participantsNCT06486883
What this trial is testing

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

Who this might be right for
Advanced Breast CancerAdvanced Breast CarcinomaHormone Receptor Positive Breast Carcinoma
MedSIR 200
Testing effectiveness (Phase 2)Looking for participantsNCT06832202
What this trial is testing

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Who this might be right for
HER2-low Hormone Receptor Positive Breast Cancer
Shanghai Henlius Biotech 50
Testing effectiveness (Phase 2)Looking for participantsNCT07796880
What this trial is testing

Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Who this might be right for
Hormone Receptor-Positive Breast CancerHER2 Low Breast CarcinomaEarly-Stage Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 80
1,978